NLS Affibody

Affibody, Acelyrin and Inmagene Biopharmaceuticals have announced that a 16-week, global, Phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) met its primary endpoint of ACR50. Izokibep also achieved secondary endpoints, including PASI response, enthesitis LEEDs improvement, and quality of life improvement on a clinically validated PsA-specific quality of life instrument, […]

Lokon Pharma has announced a collaboration with Affibody to combine oncolytic viruses with Affibody molecules. “Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already have one virus in clinical development, LOAd703, and we are expanding our pipeline to meet the demand of different types of malignancies” says […]

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals, have announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a pre-specified interim analysis. The double-blind, placebo-controlled Phase 2 clinical trial, designed and conducted by Affibody, evaluated the safety and efficacy of izokibep dosed 80 mg every […]

Affibody has announced a partnership agreement with ACELYRIN to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases. Under the terms of the agreement, Affibody will receive a USD 25 million upfront payment and is eligible to receive up to USD 280 million in additional regulatory and sales milestones, plus […]

The US FDA has cleared the novel interleukin-17 (IL-17) blocker izokibep (ABY-035) to proceed to Phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis. “Uveitis is one of the leading causes of blindness worldwide. Through the years, we have learned much about the role of IL-17 in the pathogenesis of non-infectious uveitis; thus, we […]

Affibody and Inmagene Biopharmaceuticals has announced that the FDA has cleared izokibep (ABY-035) to proceed to Phase 2 clinical development in Ankylosing Spondylitis (AS), a subset of Axial Spondyloarthritis (axSpA). The partners are jointly developing izokibep to treat multiple autoimmune diseases, and Inmagene has taken the responsibility to manage the global clinical trials for axSpA. […]